Biologics are targeted therapies composed of monoclonal antibodies that inhibit specific
inflammatory pathways involved in allergic disease. By blocking key mediators, they reduce
airway and systemic inflammation.
Biologic therapy is indicated for patients 6 months and older with moderate to severe or poorly
controlled allergic or eosinophilic conditions despite optimized standard therapy.
Biologics are approved for and commonly used in the management of asthma, atopic
dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and select
patients with COPD.
Biologics are administered via subcutaneous injection at intervals that vary by medication.
Many are FDA-approved for self-administration at home following appropriate training.
Biologics are generally well tolerated with a favorable safety profile. The most common
adverse effects are mild injection site reactions. Serious adverse events are uncommon.
For appropriately selected patients, biologic therapy can result in significant clinical
improvement, including reduced exacerbations, improved symptom control, and enhanced
quality of life.